Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk

Some health concerns are often not identified until late into clinical development of drugs, which can place participants and patients at significant risk. For example, the United States Food and Drug Administration (FDA) labeled the xanthine oxidase inhibitor febuxostat with a”boxed” warning regard...

Descripción completa

Detalles Bibliográficos
Autores principales: Feaver, Ryan E., Bowers, M. Scott, Cole, Banumathi K., Hoang, Steve, Lawson, Mark J., Taylor, Justin, LaMoreaux, Brian D., Zhao, Lin, Henke, Brad R., Johns, Brian A., Nyborg, Andrew C., Wamhoff, Brian R., Figler, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10490929/
https://www.ncbi.nlm.nih.gov/pubmed/37682977
http://dx.doi.org/10.1371/journal.pone.0291330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10490929/
https://www.ncbi.nlm.nih.gov/pubmed/37682977
http://dx.doi.org/10.1371/journal.pone.0291330

Ejemplares similares